2024-06-05 14:43:16 ET
Summary
- The stock of Elanco Animal Health Incorporated has more than doubled off its recent lows in late October.
- Product launches should boost revenue growth from 2% to 3% in FY2024 to 4% to 5% in FY2025.
- It should be noted that the company carries a good slug of long-term debt on its balance sheet, and the stock pays no dividends.
- Does the stock have further to run, or is it likely to see profit-taking in the months ahead? An analysis follows in the paragraphs below.
Today, we are putting Elanco Animal Health Incorporated ( ELAN ) in the spotlight. The company's stock has more than doubled from the lows of late October when the summer swoon within the overall market ended. That seems an enormous move for a large animal health concern. Does the rally have " paws" or are the shares likely to see some profit taking in the months ahead? An analysis around Elanco follows below....
Read the full article on Seeking Alpha
For further details see:
Elanco Animal Health: At Least Fully Valued After Rally